Advertisement

Digestive Diseases and Sciences

, Volume 61, Issue 8, pp 2185–2193 | Cite as

Diagnosis and Surveillance of Barrett’s Esophagus: Addressing the Transatlantic Divide

  • Saad Ghaus
  • Helmut Neumann
  • Humayun Muhammad
  • Gian Eugenio Tontini
  • Sauid Ishaq
Review

Abstract

Background

Barrett’s esophagus is a premalignant condition of the esophagus leading to esophageal adenocarcinoma. No consensus exists between the UK and USA concerning the diagnosis of Barrett’s esophagus. Although the diagnostic procedure is common, the required findings and diagnostic criteria vary. Both guidelines require endoscopy showing columnar epithelia lining the esophagus, but the US guidelines require the additional finding of intestinal metaplasia on biopsy to confirm diagnosis. Achievement of a consensus is of particular importance due to the established progression from Barrett’s esophagus to esophageal adenocarcinoma. Of further importance is the increasing incidence of esophageal adenocarcinoma, a condition with poor overall survival, leading to various opinions on the utility of surveillance in patients.

Discussion

A review of the vast array of literature revealed that substantial evidence exists in favor of both diagnostic criteria; hence, there is no easy way to identify the “correct” method of diagnosing Barrett’s esophagus. USA recommends surveillance of Barrett’s esophagus, whereas UK does not advocate it unless dysplasia is present. Surveillance was found to be effective, but this varied as did cost-effectiveness.

Summary

Further research into diagnostic methods for Barrett’s esophagus is needed to address areas of limited understanding, such that agreement can be reached and practice standardized. Surveillance was generally advocated, but with different criteria and time intervals, and new methods are being evaluated.

Keywords

Barrett’s esophagus Diagnosis Endoscopy Intestinal metaplasia Surveillance 

Notes

Acknowledgments

The authors were involved in the concept development, research, and writing of this article.

Author contributions

All authors conceived and wrote manuscript. All authors read and approved final manuscript.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no competing interests.

References

  1. 1.
    Spechler SJ, Goyal RK. Barrett’s esophagus. N. Engl. J. Med. 1986;315:362–371.CrossRefPubMedGoogle Scholar
  2. 2.
    Dulai GS, Guha S, Kahn KL, Gornbein J, Weinstein WM. Preoperative prevalence of Barrett’s esophagus in esophageal adenocarcinoma: a systematic review. Gastroenterology. 2002;122:26–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Shaheen N. Is there a Barrett’s iceberg? Gastroenterology. 2002;123:636–639.CrossRefPubMedGoogle Scholar
  4. 4.
    Coleman HG, Bhat S, Murray LJ, McManus D, Gavin AT, Johnston BT. Increasing incidence of Barrett’s oesophagus: a population-based study. Eur. J. Epidemiol. 2011;26:739–745.CrossRefPubMedGoogle Scholar
  5. 5.
    Devesa SS, Blot WJ, Fraumeni JF Jr. Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer. 1998;83:2049–2053.CrossRefPubMedGoogle Scholar
  6. 6.
    Corley DA, Kubo A, Levin TR, et al. Abdominal obesity and body mass index as risk factors for Barrett’s esophagus. Gastroenterology. 2007;133:34–41. (quiz 311).CrossRefPubMedGoogle Scholar
  7. 7.
    Brown LM, Devesa SS. Epidemiologic trends in esophageal and gastric cancer in the United States. Surg. Oncol. Clin. N. Am. 2002;11:235–256.CrossRefPubMedGoogle Scholar
  8. 8.
    Aida J, Vieth M, Shepherd N, et al. Is carcinoma in columnar-lined esophagus always located adjacent to intestinal metaplasia? Am. J. Surg. Pathol. 2015;39:188–196.CrossRefPubMedGoogle Scholar
  9. 9.
    Alvarez Herrero L, Curvers W, van Vilsteren F, et al. Validation of the Prague C&M classification of Barrett’s esophagus in clinical practice. Endoscopy. 2013;45:876–882.CrossRefPubMedGoogle Scholar
  10. 10.
    Armstrong D. Review article: towards consistency in the endoscopic diagnosis of barrett’s oesophagus and columnar metaplasia. Aliment. Pharmacol. Ther. 2004;20:40–47.CrossRefPubMedGoogle Scholar
  11. 11.
    Hoshihara Y, Kogure T. What are longitudinal vessels? Endoscopic observation and clinical significance of longitudinal vessels in the lower esophagus. Esophagus. 2006;3:145–150.CrossRefGoogle Scholar
  12. 12.
    American Gastroenterological Association, Spechler SJ, Sharma P, Souza RF, Inadomi JM, Shaheen NJ. American gastroenterological association medical position statement on the management of barrett’s esophagus. Gastroenterology. 2011;140:1084–1091.CrossRefGoogle Scholar
  13. 13.
    Repaka A, Chak A. Endoscopic management of Barrett esophagus. Nat. Rev. Gastroenterol. Hepatol. 2011;8:582–591.CrossRefPubMedGoogle Scholar
  14. 14.
    Sharma P, Brill J, Canto M, et al. White Paper AGA: advanced imaging in Barrett’s Esophagus. Clin. Gastroenterol. Hepatol. 2015;13:2209–2218.CrossRefPubMedGoogle Scholar
  15. 15.
    Paull A, Trier JS, Dalton MD, Camp RC, Loeb P, Goyal RK. The histologic spectrum of Barrett’s esophagus. N. Engl. J. Med. 1976;295:476–480.CrossRefPubMedGoogle Scholar
  16. 16.
    Liu W, Hahn H, Odze RD, Goyal RK. Metaplastic esophageal columnar epithelium without goblet cells shows DNA content abnormalities similar to goblet cell-containing epithelium. Am. J. Gastroenterol. 2009;104:816–824.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Faller G, Borchard F, Ell C, et al. Histopathological diagnosis of Barrett’s mucosa and associated neoplasias: results of a consensus conference of the Working Group for Gastroenterological Pathology of the German Society for Pathology on 22 September 2001 in Erlangen. Virchows Archiv. 2003;443:597–601. doi: 10.1038/ajg.2015.116.CrossRefPubMedGoogle Scholar
  18. 18.
    Curvers WL, ten Kate FJ, Krishnadath KK, et al. Low-grade dysplasia in Barrett’s esophagus: overdiagnosed and underestimated. Am. J. Gastroenterol. 2010;105:1523–1530.CrossRefPubMedGoogle Scholar
  19. 19.
    Weinstein WM, Ippoliti AF. The diagnosis of Barrett’s esophagus: goblets, goblets, goblets. Gastrointest. Endosc. 1996;44:91–95.CrossRefPubMedGoogle Scholar
  20. 20.
    Shaheen N, Falk G, Iyer P, Gerson L. ACG clinical guideline: diagnosis and management of Barrett’s Esophagus. Am. J. Gastroenterol. 2016;111:30–50.CrossRefPubMedGoogle Scholar
  21. 21.
    Fitzgerald R, Di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014;63:7–42.CrossRefPubMedGoogle Scholar
  22. 22.
    Khandwalla H, Graham D, Kramer J, et al. Corrigendum: Barrett’s Esophagus suspected at endoscopy but no specialized intestinal metaplasia on biopsy, what’s next? Am. J. Gastroenterol. 2014;109:1123.CrossRefGoogle Scholar
  23. 23.
    Harrison R, Perry I, Haddadin W, et al. Detection of intestinal metaplasia in Barrett’s esophagus: an observational comparator study suggests the need for a minimum of eight biopsies. Am. J. Gastroenterol. 2007;102:1154–1161.CrossRefPubMedGoogle Scholar
  24. 24.
    Kelty C, Gough M, Van Wyk Q. Barrett’s oesophagus: intestinal metaplasia is not essential for cancer risk. Scand. J. Gastroenterol. 2007;42:1271–1274.CrossRefPubMedGoogle Scholar
  25. 25.
    Chandrasoma P. Diagnostic atlas of gastroesophageal reflux disease. Amsterdam: Elsevier/Academic Press; 2007.Google Scholar
  26. 26.
    Rothstein F, Dahms B. Barrett’s esophagus in children. In: Spechler SJ, Goyal R, eds. Barrett’s Esophagus: pathophysiology, diagnosis, and management. New York: Elseiver; 1985.Google Scholar
  27. 27.
    Smith RR, Hamilton SR, Boitnott JK, Rogers EL. The spectrum of carcinoma arising in Barrett’s esophagus. A clinicopathologic study of 26 patients. Am. J. Surg. Pathol. 1984;8:563–573.CrossRefPubMedGoogle Scholar
  28. 28.
    Riddell RH, Odze RD. Definition of Barrett’s esophagus: time for a rethink—Is intestinal metaplasia dead? Am. J. Gastroenterol. 2009;104:2588–2594.CrossRefPubMedGoogle Scholar
  29. 29.
    Gatenby PAC, Ramus JR, Caygill CP, Shepherd NA, Watson A. Relevance of the detection of intestinal metaplasia in non dysplastic columnar lined esophagus. Scand. J. Gastroenterol. 2008;43:524–530.CrossRefPubMedGoogle Scholar
  30. 30.
    Sharma P, McQuaid K, Dent J, et al. A critical review of the diagnosis and management of Barrett’s esophagus: the AGA Chicago Workshop. Gastroenterology. 2004;127:310–330.CrossRefPubMedGoogle Scholar
  31. 31.
    Chandrasoma P, Wickramasinghe K, Ma Y, DeMeester TR. Is intestinal metaplasia a necessary precursor lesion for adenocarcinomas of the distal esophagus, gastroesophageal junction and gastric cardia? Dis. Esophagus. 2007;20:36–41.CrossRefPubMedGoogle Scholar
  32. 32.
    Chandrasoma P, Wijetunge S, DeMeester S, et al. Columnar-lined esophagus without intestinal metaplasia has no proven risk of adenocarcinoma. Am. J. Surg. Pathol. 2012;36:1–7.CrossRefPubMedGoogle Scholar
  33. 33.
    Levine DS, Haggitt RC, Blount PL, et al. An endoscopic biopsy protocol can differentiate high-grade dysplasia from early adenocarcinoma in Barrett’s esophagus. Gastroenterology. 1993;105:40–50.CrossRefPubMedGoogle Scholar
  34. 34.
    Kariv R, Plesec T, Goldblum J, et al. The seattle protocol does not more reliably predict the detection of cancer at the time of esophagectomy than a less intensive surveillance protocol. Clin. Gastroenterol. Hepatol. 2009;7:653–658.CrossRefPubMedGoogle Scholar
  35. 35.
    Ishaq S, Harper E, Brown J. Survey of current clinical practice in the diagnosis, management and surveillance of Barrett’s metaplasia: a UK national survey. Gut. 2003;53:A32.Google Scholar
  36. 36.
    Das D, Ishaq S, Harrison R, et al. Management of Barrett’s esophagus in the UK: overtreated and underbiopsied but improved by the introduction of a national randomized trial. Am. J. Gastroenterol. 2008;103:1079–1089.CrossRefPubMedGoogle Scholar
  37. 37.
    Abrams JA, Kapel RC, Lindberg GM, et al. Adherence to biopsy guidelines for Barrett’s esophagus surveillance in the community setting in the United States. Clin. Gastroenterol. Hepatol. 2009;7:736–742.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Bennett C, Moayyedi P, Corley DA, et al. BOB CAT: a large-scale review and Delphi consensus for management of Barrett’s Esophagus with no dysplasia, indefinite for, or low-grade dysplasia. Am. J. Gastroenterol. 2015;110:662–682.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Schlemper RJ, Kato Y, Stolte M. Review of histological classifications of gastrointestinal epithelial neoplasia: differences in diagnosis of early carcinomas between Japanese and Western pathologists. J. Gastroenterol. 2001;36:445–456.CrossRefPubMedGoogle Scholar
  40. 40.
    Desai TK, Krishnan K, Samala N, et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett’s oesophagus: a meta-analysis. Gut. 2012;61:970–976.CrossRefPubMedGoogle Scholar
  41. 41.
    Moayyedi P, Burch N, Akhtar-Danesh N, et al. Mortality rates in patients with Barrett’s oesophagus. Aliment. Pharmacol. Ther. 2008;27:316–320.CrossRefPubMedGoogle Scholar
  42. 42.
    Wani S, Falk GW, Post J, et al. Risk factors for progression of low-grade dysplasia in patients with Barrett’s esophagus. Gastroenterology. 2011;141:1179–1186, 1186 e1.CrossRefPubMedGoogle Scholar
  43. 43.
    Fountoulakis A, Zafirellis KD, Dolan K, Dexter SP, Martin IG, Sue-Ling HM. Effect of surveillance of Barrett’s oesophagus on the clinical outcome of oesophageal cancer. Br. J. Surg. 2004;91:997–1003.CrossRefPubMedGoogle Scholar
  44. 44.
    Sonnenberg A, Soni A, Sampliner R. Medical decision analysis of endoscopic surveillance of Barrett’s oesophagus to prevent oesophageal adenocarcinoma. Aliment. Pharmacol. Ther. 2002;16:41–50.CrossRefPubMedGoogle Scholar
  45. 45.
    Kastelein F, van Olphen S, Steyerberg E, et al. Surveillance in patients with long-segment Barrett’s oesophagus: a cost-effectiveness analysis. Gut. 2014;64:864–871.CrossRefPubMedGoogle Scholar
  46. 46.
    Macdonald CE, Wicks AC, Playford RJ. Final results from 10 year cohort of undergoing surveillance for Barrett’s oesophagus: observational study. BMJ. 2000;321:1252–1255.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Corley D, Mehtani K, Quesenberry C, Zhao W, de Boer J, Weiss N. Impact of endoscopic surveillance on mortality from Barrett’s Esophagus-associated esophageal adenocarcinomas. Gastroenterology. 2013;145:312–319.e1.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Bhat S, Coleman H, Yousef F, et al. Risk of malignant progression in Barrett’s Esophagus patients: results from a large population-based study. J. Natl. Cancer Inst. 2011;103:1049–1057.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Cooper SC, El-agib A, Dar S, et al. Endoscopic surveillance for Barrett’s oesophagus: the patients’ perspective. Eur. J. Gastroenterol. Hepatol. 2009;21:850–854.CrossRefPubMedGoogle Scholar
  50. 50.
    Nice.org.uk. Dyspepsia and gastroesophageal reflux disease | key-priorities-for-implementation | Guidance and guidelines | NICE http://www.nice.org.uk/guidance/cg184/chapter/key-priorities-for-implementation#surveillance-for-people-with-barretts-esophagus. Accessed October 25, 2014.

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Saad Ghaus
    • 1
    • 2
  • Helmut Neumann
    • 3
  • Humayun Muhammad
    • 1
  • Gian Eugenio Tontini
    • 4
  • Sauid Ishaq
    • 1
    • 5
  1. 1.Gastroenterology Department, Dudley Group HospitalsBirmingham City UniversityBirminghamUK
  2. 2.University of BirminghamBirminghamUK
  3. 3.Department of MedicineUniversity Hospital ErlangenErlangenGermany
  4. 4.Gastroenterology and Digestive Endoscopy UnitIRCCS Policlinico San DonatoSan Donato MilaneseItaly
  5. 5.St. George’s UniversitySt. GeorgeGrenada, West Indies

Personalised recommendations